000181427 001__ 181427
000181427 005__ 20240301125646.0
000181427 0247_ $$2doi$$a10.1093/neuonc/nox191
000181427 0247_ $$2pmid$$apmid:29040782
000181427 0247_ $$2pmc$$apmc:PMC5961011
000181427 0247_ $$2ISSN$$a1522-8517
000181427 0247_ $$2ISSN$$a1523-5866
000181427 0247_ $$2altmetric$$aaltmetric:27273331
000181427 037__ $$aDKFZ-2022-01995
000181427 041__ $$aEnglish
000181427 082__ $$a610
000181427 1001_ $$aEskilsson, Eskil$$b0
000181427 245__ $$aEGFR heterogeneity and implications for therapeutic intervention in glioblastoma.
000181427 260__ $$aOxford$$bOxford Univ. Press$$c2018
000181427 3367_ $$2DRIVER$$aarticle
000181427 3367_ $$2DataCite$$aOutput Types/Journal article
000181427 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1661342849_30652$$xReview Article
000181427 3367_ $$2BibTeX$$aARTICLE
000181427 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000181427 3367_ $$00$$2EndNote$$aJournal Article
000181427 500__ $$aPOT Topic: 317
000181427 520__ $$aPatients with glioblastoma (GBM) have a universally poor prognosis and are in urgent need of effective treatment strategies. Recent advances in sequencing techniques unraveled the complete genomic landscape of GBMs and revealed profound heterogeneity of individual tumors even at the single cell level. Genomic profiling has detected epidermal growth factor receptor (EGFR) gene alterations in more than half of GBMs. Major genetic events include amplification and mutation of EGFR. Yet, treatment strategies targeting EGFR have thus far failed in clinical trials. In this review, we discuss the clonal and functional heterogeneity of EGFRs in GBM development and critically reassess the potential of EGFRs as therapeutic targets.
000181427 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000181427 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000181427 650_7 $$2NLM Chemicals$$aProtein Kinase Inhibitors
000181427 650_7 $$0EC 2.7.10.1$$2NLM Chemicals$$aEGFR protein, human
000181427 650_7 $$0EC 2.7.10.1$$2NLM Chemicals$$aErbB Receptors
000181427 650_2 $$2MeSH$$aErbB Receptors: antagonists & inhibitors
000181427 650_2 $$2MeSH$$aErbB Receptors: genetics
000181427 650_2 $$2MeSH$$aGlioblastoma: drug therapy
000181427 650_2 $$2MeSH$$aGlioblastoma: genetics
000181427 650_2 $$2MeSH$$aGlioblastoma: pathology
000181427 650_2 $$2MeSH$$aHumans
000181427 650_2 $$2MeSH$$aMolecular Targeted Therapy
000181427 650_2 $$2MeSH$$aMutation
000181427 650_2 $$2MeSH$$aPrognosis
000181427 650_2 $$2MeSH$$aProtein Kinase Inhibitors: therapeutic use
000181427 7001_ $$aRøsland, Gro V$$b1
000181427 7001_ $$0P:(DE-He78)aceff95b461bf57aaa3c92ea45b28233$$aSolecki, Gergely Morten$$b2
000181427 7001_ $$aWang, Qianghu$$b3
000181427 7001_ $$aHarter, Patrick N$$b4
000181427 7001_ $$aGraziani, Grazia$$b5
000181427 7001_ $$aVerhaak, Roel G W$$b6
000181427 7001_ $$0P:(DE-He78)6c294453ee36ad59deddc5494fa6aa4b$$aWinkler, Frank$$b7$$udkfz
000181427 7001_ $$aBjerkvig, Rolf$$b8
000181427 7001_ $$aMiletic, Hrvoje$$b9
000181427 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/nox191$$gVol. 20, no. 6, p. 743 - 752$$n6$$p743 - 752$$tNeuro-Oncology$$v20$$x1522-8517$$y2018
000181427 909CO $$ooai:inrepo02.dkfz.de:181427$$pVDB
000181427 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)aceff95b461bf57aaa3c92ea45b28233$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000181427 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c294453ee36ad59deddc5494fa6aa4b$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000181427 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000181427 9141_ $$y2018
000181427 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2021-02-03$$wger
000181427 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-02-03
000181427 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-02-03
000181427 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-02-03
000181427 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-02-03
000181427 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-03
000181427 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-02-03
000181427 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-03
000181427 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-02-03
000181427 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2019$$d2021-02-03
000181427 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bNEURO-ONCOLOGY : 2019$$d2021-02-03
000181427 9201_ $$0I:(DE-He78)G370-20160331$$kG370$$lKKE Neuroonkologie$$x0
000181427 980__ $$ajournal
000181427 980__ $$aVDB
000181427 980__ $$aI:(DE-He78)G370-20160331
000181427 980__ $$aUNRESTRICTED